Keyword: American Diabetes Association
AZ may not yet have the same outcomes data for Farxiga that its SGLT2 rivals can boast, but the company thinks it may have something better.
The ADA's treatment recommendation could help drive Vascepa sales past Amarin's $350 million projection for the year, an analyst says.
Novo Nordisk’s next big hope is an oral version of its new launch, Ozempic (semaglutide), and the data in its favor just keeps piling up.
In 2015, BI and Eli Lilly were the first to show that a diabetes med could cut the risk of CV death, and they’re still working to capitalize on that.
Competition in every class of diabetes medications is getting tougher, with CV data now de rigueur.
The American Diabetes Association has recommended Eli Lilly and Boehringer Ingelheim's Jardiance in its official guidelines for 2017.
AntriaBio, a biopharma focused on developing novel extended-release therapies, has raised $12 million in a private placement deal.
Earlier this year, Novo Nordisk’s Victoza became the second diabetes drug to lower cardiovascular risks in a clinical trial. Now, we know by just how much.
Diabetes researchers, endocrinologists and primary care docs, patient advocacy groups and, of course, media descended on New Orleans to catch the latest. Here's the need-to-know news.
Combining metformin with insulin in the treatment of Type 2 diabetes has been found to reduce the risk of mortality, according to a new study.